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Background
TGF-beta 1 (TGF), is one of the potent profibrotic factors
which plays a fundamental role in myocardial remode-
ling. Cardiac fibrosis results from excessive deposition of
extracellular matrix including collagen type I (Col I)
which is mainly produced by cardiac fibroblasts. CD-NP
is a novel engineered designer natriuretic peptide (NP)
which consists of the ring structure of human C-type NP
(CNP) and the C-terminal tail of Dendroaspis NP (DNP).
This unique chimeric represents the first dual particulate
gaunylyl cyclase receptor activator known to co-activate
both natriuretic peptide receptor (NPR)-A and NPR-B.
Previously we reported that CD-NP stimulates the produc-
tion of the NPR-A/B and the second messenger cyclic gua-
nosine monophosphate (cGMP) in human cardiac
fibroblasts (CFs). Here we hypothesized that CD-NP
would suppress Col I expression stimulated by TGF in
CFs.
Methods
CFs were cultured in fibroblast media on non-coated
plates and passages 2 though 5 were used for experiments.
Protein expression of NP receptors in CFs was determined
by immunocytochemistry using custom made NP recep-
tor antibodies. Col I protein expression was determined
by commercially available Enzyme-linked immunosorb-
ent assay kits. After 30 minutes preincubation with or
without CD-NP (10-8 to 10-6 mol/l), cells were treated
with or without TGF (5 or 10 ng/ml) for 48 hours.
Results
Immunocytochemistry confirmed expression of all three
NPRs; NPR-A, NPR-B, and NPR-C in human CFs. Col I
protein expression was significantly increased by treat-
ment with 10 ng/ml TGF for 48 hours (p < 0.0001). TGF
stimulated Col I protein expression demonstrated 20%
inhibition by 10-6 mol/L CD-NP (p < 0.0001).
Conclusion
Human cardiac fibroblasts express all NPs receptors. CD-
NP suppresses TGF-beta 1 enhanced Col I production in
CFs. These results suggest that CD-NP may play therapeu-
tic role as an anti-fibrotic peptide in cardiac remodeling
warranting further studies in models of cardiac fibrosis.
Circulating corin increases with age and is higher in males
than females, which may have physiologic and patho-
physiologic implications on NP processing.
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